By continuing an open discussion on precision medicine and precision care, we can truly accelerate pharmacogenomic testing to its full potential and focus on providing the highest quality care to those who need it most.
All the hype around precision medicine can make it seem intimidating and foreign. The good news is that it does not represent a departure from current clinical practice, and it can significantly improve patient care.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As researchers and clinicians understand and embrace the advanced insights genetic and genomic testing can deliver, the industry is poised to dramatically reduce the incidence and mortality associated with cancers.
Unless IT concerns related to precision medicine are addressed, healthcare will simply reenact a mistake made years ago with EHRS valuable data that can directly impact care will be locked in a silo, unavailable during clinical decision-making.
Healthcare leaders have an opportunity to build their infrastructure right this time – with foresight into how valuable genomic data will be to all their stakeholders, now and into the future.
Not all direct-to-consumer tests tell the truth, the whole truth, and nothing but the truth. So where do modern consumers stand?
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.